Roche Breast Cancer Drug Giredestrant Granted FDA Priority Review

The U.S. Food and Drug Administration (FDA) has granted priority review status to Roche's breast cancer drug, giredestrant. This designation accelerates the review process for drugs that could offer significant improvements over existing treatments.